Green light for GSK/Pfizer acquisition


green light new law approval
The ACCC has announced that it will not oppose GSK’s proposed acquisition of Pfizer’s consumer healthcare business in Australia The proposed acquisition combines only the over-the-counter side of the two businesses, which include well-known analgesic products such as Panadol, Voltaren and Advil, as well as gastrointestinal and cold and flu products. The Australian Competition and

This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous GP-pharmacist relationships improving
Next Inadvertent harms